Lung cancer recurrence after neoadjuvant immunotherapy Objectives: To investigate recurrence risk and patterns following neoadjuvant immunotherapy (Neo-IO) for resectable lung cancer, with a focus on identifying optimal cutoffs of residual viable tumor percentage (%RVT) of the primary tumor as a prognostic indicator
Lung cancer recurrence after neoadjuvant immunotherapy We conducted a retrospective analysis of patients with resectable non–small cell lung cancer who received Neo-IO with or without chemotherapy followed by lung resection, using data from our prospectively maintained clinical database
Lung cancer recurrence after neoadjuvant immunotherapy To investigate recurrence risk and patterns following neoadjuvant immunotherapy (Neo-IO) for resectable lung cancer, with a focus on identifying optimal cutoffs of residual viable tumor percentage (%RVT) of the primary tumor as a prognostic indicator
Lung Cancer Recurrence after Neoadjuvant Immunotherapy Perspective Statement: This study identified the percentage of residual viable tumor (%RVT) of the primary tumor in the surgical specimen as an independent risk factor for lung cancer recurrence following neoadjuvant chemoimmunotherapy and resection, highlighting the potential of stratifying patients by %RVT to optimize adjuvant treatment
Lung Cancer Recurrence after Neoadjuvant Immunotherapy Updated monthly, the Nature Index presents research outputs by institution and country Use the Nature Index to interrogate publication patterns and to benchmark research performance
Lung Cancer Surgery after Neoadjuvant Immunotherapy - MDPI In early-stage lung cancer, recurrences are observed even after curative resection Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival
Frontiers | Neoadjuvant immunotherapy for lung cancer: current . . . This review aims to comprehensively summarize the latest clinical evidence on neoadjuvant immunotherapy for lung cancer, delve into the main challenges and opportunities encountered in clinical practice, and explore its future directions, including novel combination therapies, personalized treatment strategies, and the application of innovative
Lung Cancer Recurrence after Neoadjuvant Immunotherapy Request PDF | On May 1, 2025, Hao Li and others published Lung Cancer Recurrence after Neoadjuvant Immunotherapy | Find, read and cite all the research you need on ResearchGate
Prognosis and relapse patterns in patients with non-small cell lung . . . We retrospectively analyzed patients with stage IB to IIIB NSCLC who had pCR after treatment with immunochemotherapy and surgery at four high-volume medical centers from 2018 to 2022 Survival status and patterns of relapse were determined